FDA red and green lights: July 2025
Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
There are questions about vuso-vec’s supporting and confirmatory trials.
But some phase 3 details are unconfirmed, and phase 2 data haven’t shed light on the biggest question.
The group eyes a broader use than Immunocore’s Kimmtrak.
The company’s vuso-vec looks similar to Amtagvi, and could have safety and convenience advantages.